DNL919
Alzheimer's disease
Phase 1bActive
Key Facts
About Denali Therapeutics
Denali Therapeutics is a public biotech company focused on discovering, developing, and delivering medicines for serious diseases, with a particular emphasis on crossing biological barriers to reach the brain. The company's proprietary TransportVehicle™ platform is central to its strategy, aiming to transform treatment for neurodegenerative and lysosomal storage disorders. Denali has built a diverse clinical-stage pipeline through both internal R&D and strategic partnerships, positioning itself at the forefront of next-generation CNS therapeutics. The company is headquartered in South San Francisco, California, and trades on the NASDAQ under the ticker DNLI.
View full company profileOther Alzheimer's disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Donanemab | Eli Lilly | Phase 3 |
| ALN-APP | Alnylam Pharmaceuticals | Phase 1 |
| Alzheimer's Disease Program | Roche | Various |
| UCB0022 | UCB | Phase 1 |
| Lecanemab (Leqembi) | Eisai | Commercial |
| ARO-MAPT | Arrowhead Pharmaceuticals | Pre-clinical |
| AMBAR® | Grifols | Clinical |
| Lu AG08854 (L1CAM mAb) | Lundbeck | Preclinical |
| BAN2802 | BioArctic AB | Preclinical |
| Lecanemab SC | BioArctic AB | Phase 3 |
| Undisclosed Program | uniQure | Preclinical |
| NVG-291 | NervGen Pharma | Phase 1b/2a |